Abstract:Background: Medullary thyroid carcinoma (MTC) accounts for 5% of all thyroid carcinomas. As no effective systemic therapy exists, surgery is the only curative treatment for MTC. In the last few years, several clinical trials have tested the efficacy of new multi-targeted agents such as sorafenib, vandetanib, motesanib, sunitinib and pazopanib in patients with metastatic MTC.
Summary:In June 2010, a 38-year-old male patient complained of pain on swallowing and coughs. Physical examination detected a hard nodule… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.